First Wave BioPharma to Present at 2023 Roth Healthcare Opportunities Conference

First Wave BioPharma, a leading clinical-stage biopharmaceutical company specializing in targeted therapies for gastrointestinal (GI) diseases, has announced that its Chairman, President, and CEO, James Sapirstein, will be giving a presentation at the upcoming 2023 Roth Healthcare Opportunities Conference. The event is scheduled to take place on October 12, 2023, in New York City.

During the conference, members of the First Wave BioPharma management team will also be conducting one-on-one meetings with registered investors. These meetings will provide an opportunity for the team to showcase the company’s business and clinical development strategy, recent achievements, and anticipated milestones.

First Wave BioPharma is focused on advancing its therapeutic development pipeline, which includes multiple Phase 2 clinical stage programs. The company’s pipeline is built around three proprietary technologies: capeserod, a selective 5-HT4 receptor partial agonist for gastrointestinal indications; adrulipase, a biologic recombinant lipase enzyme designed to aid digestion in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases.

Headquartered in Boca Raton, Florida, First Wave BioPharma is committed to developing innovative therapies that address the unmet needs of patients with GI diseases. For more information about the company and its pipeline, please visit www.firstwavebio.com.

Media Contact:
Tiberend Strategic Advisors, Inc.
David Schemelia
Phone: (609) 468-9325
Email: dschemelia@tiberend.com